Researchers at Stanford have found that a vaccine, enhanced with adjuvants that imprint an antiviral state on innate immune cells and non-hematopoietic organ cells, could confer lasting nonspecific protection against diverse pathogens.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Stanford scientists have developed broadly neutralizing antibodies against sarbecoviruses , including SARS-CoV-2 related Clade 1b, SARS-CoV related Clade 1a and Clade 3 viruses, paving the way for future vaccines and therapeutics.
Stanford researchers have developed a multi-omics method for predicting the strength and durability of immune responses to vaccines shortly after vaccination. The COVID-19 pandemic was a grave demonstration of the threat pandemics pose to global public health.